Sean Plummer
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Researcher
Also affiliated: Massachusetts General Hospital (2017–2024); Center for Cancer Research (2024–2025); Texas A&M University (2020–2026)
Unknown Researcher
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Sean Plummer's research focuses on the treatment of mantle cell lymphoma (MCL), particularly in patients with a TP53 mutation. His work investigates the efficacy of combination chemotherapy regimens, including zanubrutinib, obinutuzumab, and venetoclax, for first-line treatment. Plummer has published findings on the durable responses achieved with this treatment approach, especially in patients who achieve undetectable minimal residual disease (MRD). His publications also explore post-treatment outcomes and the long-term benefits for these patient populations. Plummer's scholarly metrics include an h-index of 3, with 7 total publications and 265 citations.
Metrics
- h-index: 3
- Publications: 5
- Citations: 268
Selected Publications
-
Evidence Bounds in Singular Models: Probabilistic and Variational Perspectives (2026)
Collaboration Network
Top Collaborators
- Evidence Bounds in Singular Models: Probabilistic and Variational Perspectives
- Evidence Bounds in Singular Models: Probabilistic and Variational Perspectives
Similar Researchers
Based on overlapping research topics